Towards harmonization of voriconazole CLSI and EUCAST breakpoints for Candida albicans using a validated in vitro pharmacokinetic/pharmacodynamic model.

Maria-Ioanna Beredaki,Panagiota-Christina Georgiou,Maria Siopi,Lamprini Kanioura,David R. Andes,Maiken Cavling Arendrup,Johan W. Mouton,Joseph Meletiadis

Towards harmonization of voriconazole CLSI and EUCAST breakpoints for Candida albicans using a validated in vitro pharmacokinetic/pharmacodynamic model.

2020

Maria-Ioanna Beredaki
Panagiota-Christina Georgiou
Maria Siopi
Lamprini Kanioura
David R. Andes
Maiken Cavling Arendrup
Johan W. Mouton
Joseph Meletiadis

Background. CLSI and EUCAST susceptibility breakpoints for voriconazole and C. albicans differ by one dilution ( 95% PTAs were found for EUCAST/CLSI MICs

Keywords:

Microbiology
Voriconazole
Breakpoint
Pharmacodynamics
Biology
In vitro
Candida albicans
Corpus albicans
Pharmacokinetics
PK/PD models
Liter

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations